Takeda Pharmaceutical Company has teamed up with Charles River to deliver preclinical candidates across its four core therapeutic areas.

Under the multi-year drug discovery collaboration, the two companies will work on multiple integrated programmes for oncology, gastroenterology, neuroscience and rare disease therapeutic areas.

As agreed, Takeda will pay Charles River a one-time, upfront fee for the partnership. Charles River will also receive additional development payments that can value more than $50m per programme upon reaching preclinical and clinical milestones for candidates.

Furthermore, the agreement includes the provision of potential commercial milestone payments of up to $120m and royalties on launched drug products.

Charles River chairman, president and CEO James C. Foster said: “We are pleased to expand our relationship with Takeda, who shares our commitment to bring innovative, safe, and effective medicines to patients as quickly and efficiently as possible.

“We expect the expertise of Charles River and Takeda will prove to be a powerful combination in delivering novel drug candidates.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the collaboration, Takeda will leverage Charles River’s drug discovery expertise to support the development of drug candidates.

It will also use Charles River’s drug discovery and safety assessment platform to study therapeutic approaches and advance the programmes towards candidate status.

Subsequently, Takeda may choose to pursue clinical development of the candidates.

Takeda global head of Research Steve Hitchcock said: “Takeda has a long history of working with Charles River across our drug discovery and development portfolio and are confident in their breadth of experience and commitment to excellent science.

“Leveraging Charles River’s integrated discovery capabilities is a natural extension of our relationship.”